Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2014 03:00 ET | Source: OnCore Biopharma, Inc.

OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection

OnCore Secures Exclusive Worldwide Rights to NVP018 NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...